Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536873 · ClinicalTrials.gov registry record · NA
Dolutegravir Expanded Access Study
A NA study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT01536873: Completed NA study, sponsored by ViiV Healthcare.
NCT01536873 is a NA study that has completed, run by ViiV Healthcare. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01536873, a NA study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
ING114916 is an open-label, multi-center, expanded access (EAP) study
Primary Outcome
To to provide access in an open label protocol program to patients who have documented RAL or ELV resistance, who have limited treatment options and who require DTG to construct a viable ARV regimen for therapy
Interventions
- DRUG Dolutegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2012-06-14 |
| Est. Completion | 2016-09-23 |
| Phase | NA |
What the finished NCT01536873 record still lists
NCT01536873 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Dolutegravir is the first listed.
NCT01536873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01536873 about?
NCT01536873 is a clinical study titled "Dolutegravir Expanded Access Study". ING114916 is an open-label, multi-center, expanded access (EAP) study
What is the current status of trial NCT01536873?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2012-06-14. Estimated completion is 2016-09-23.
What interventions are being tested in trial NCT01536873?
The interventions under investigation include: Dolutegravir (DRUG).
Who is sponsoring clinical trial NCT01536873?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01536873's enrollment target sits among peer trials
200 506th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI